Grabar Law Office is investigating claims on behalf of shareholders of GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

GPGI, Inc., together with its subsidiaries, provides sustainable injection molding solutions worldwide. The company’s CompoSecure business provides metal payment cards, security, and authentication solutions. It offers engineered injection molding equipment and aftermarket tooling and services focuses on developing highly technical precision technologies instrumental in the delivery of food , beverages, medical devices, and other applications including general packaging and closures, thinwall packaging, and consumer products. The company was formerly known as CompoSecure, Inc. and changed its name to GPGI, Inc. in January 2026.

WHY? It is alleged in a recently filed federal securities fraud class action complain that GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) defendants had materially overstated the value of Husky; (ii) Husky was not on track to achieve the revenue and Adjusted EBITDA targets provided in the proxy statement and such targets lacked a reasonable basis in objective fact; (iii) a primary motivation of the Husky Acquisition was to generate millions of dollars in fees for Resolute Holdings and the individual defendants, rather than to create long-term value for CompoSecure shareholders; and (iv) as a result of the above, defendants had materially misrepresented the business, prospects, and expected financial results of GPGI and Husky as a combined business.

On March 12, 2026, GPGI announced 4Q25 and FY25 earnings and disclosed that Husky had $520.8 million in 4Q25 net sales (up 6.1% year-over-year) and $1.5687 billion in FY25 net sales (up 5% year-over-year). GPGI further disclosed that Husky had Pro Forma Adjusted EBITDA of $136.1 million in 4Q25 (down 5.4% year-over-year) and $373.4 million in FY25 (down 3% year-over-year). Notably, Husky’s Pro Forma Adjusted EBITDA margins for 4Q25 compressed by 318 basis points from 29.3% to 26.1%. On this news, the price of GPGI stock fell 16% over two trading days.

Then, on May 7, 2026, GPGI reported its 1Q26 financial results, revealing that Husky’s Pro Forma Adjusted Net Sales were just $290.8 million, down 5.2% year-over-year, and its Pro Forma Adjusted EBITDA fell to $38 million, down 40.2% year-over year. Additionally, GPGI cut 2026 guidance, with its Pro Forma Adjusted Net Sales lowered from an initial range of $2.183 billion to $2.228 billion to a range of $1.95 billion to $2.10 billion, and its Pro Forma Adjusted EBITDA lowered from an initial range of $620 million to $650 million to a range of $550 million to $610 million. On this news, the price of GPGI stock fell nearly 26%.

WHAT CAN YOU DO NOW? If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  Alternatively, if you purchased GPGI, Inc., f/k/a CompoSecure, Inc. securities between November 3, 2025 and May 6, 2026, you can participate in the class action.

#GPGI $GPGI #CompoSecure $CMPO